These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 23670184)

  • 21. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro.
    Wallis RM; Corbin JD; Francis SH; Ellis P
    Am J Cardiol; 1999 Mar; 83(5A):3C-12C. PubMed ID: 10078537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclic AMP-specific and cyclic GMP-specific phosphodiesterase isoenzymes in human cavernous arteries--immunohistochemical distribution and functional significance.
    Waldkirch E; Uckert S; Yildirim H; Sohn M; Jonas U; Stief CG; Andersson KE; Hedlund P
    World J Urol; 2005 Dec; 23(6):405-10. PubMed ID: 16292559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improving memory: a role for phosphodiesterases.
    Blokland A; Schreiber R; Prickaerts J
    Curr Pharm Des; 2006; 12(20):2511-23. PubMed ID: 16842174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in phosphodiesterase activity in the developing rat submandibular gland.
    Tanaka S; Shimooka S; Shimomura H
    Arch Oral Biol; 2002 Aug; 47(8):567-76. PubMed ID: 12221013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphodiesterase type 2 distribution in the guinea pig urinary bladder.
    Rahnama'i MS; Hohnen R; Van Kerrebroeck PE; van Koeveringe GA
    World J Urol; 2015 Oct; 33(10):1623-33. PubMed ID: 25480469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Future options for combination therapy in the management of erectile dysfunction in older men.
    Sommer F; Engelmann U
    Drugs Aging; 2004; 21(9):555-64. PubMed ID: 15260511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contribution of phosphodiesterase isoenzymes and cyclic nucleotide efflux to the regulation of cyclic GMP levels in aortic smooth muscle cells.
    Mercapide J; Santiago E; Alberdi E; Martinez-Irujo JJ
    Biochem Pharmacol; 1999 Nov; 58(10):1675-83. PubMed ID: 10535760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distribution and functional significance of phosphodiesterase isoenzymes in the human lower urinary tract.
    Uckert S; Stief CG; Mayer M; Jonas U; Hedlund P
    World J Urol; 2005 Dec; 23(6):368-73. PubMed ID: 16331503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside.
    Truss MC; Stief CG; Uckert S; Becker AJ; Wefer J; Schultheiss D; Jonas U
    World J Urol; 2001 Nov; 19(5):344-50. PubMed ID: 11760783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.
    Uckert S; Oelke M
    Br J Clin Pharmacol; 2011 Aug; 72(2):197-204. PubMed ID: 21745238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of phosphodiesterases in adult-onset pulmonary arterial hypertension.
    Murray F; Maclean MR; Insel PA
    Handb Exp Pharmacol; 2011; (204):279-305. PubMed ID: 21695645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Phosphodiesterase regulation of cardiovascular functions].
    Li L; He Q; Gao YS
    Sheng Li Ke Xue Jin Zhan; 2010 Apr; 41(2):100-6. PubMed ID: 21416994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The potential role of unregulated autonomous bladder micromotions in urinary storage and voiding dysfunction; overactive bladder and detrusor underactivity.
    Drake MJ; Kanai A; Bijos DA; Ikeda Y; Zabbarova I; Vahabi B; Fry CH
    BJU Int; 2017 Jan; 119(1):22-29. PubMed ID: 27444952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
    Cheng J; Grande JP
    Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and functional study of phosphodiesterases in rat urinary bladder.
    Qiu Y; Kraft P; Craig EC; Liu X; Haynes-Johnson D
    Urol Res; 2001 Dec; 29(6):388-92. PubMed ID: 11828991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclic nucleotide metabolism including nitric oxide and phosphodiesterase-related targets in the lower urinary tract.
    Uckert S; Kuczyk MA
    Handb Exp Pharmacol; 2011; (202):527-42. PubMed ID: 21290241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Nitric oxide pathway and female lower urinary tract. Physiological and pathophysiological role].
    Gamé X; Rischmann P; Arnal JF; Malavaud B
    Prog Urol; 2013 Sep; 23(11):926-35. PubMed ID: 24010923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The management of phosphodiesterase-5 (PDE5) inhibitor failure.
    Lau DH; Kommu S; Mumtaz FH; Morgan RJ; Thompson CS; Mikhailidis DP
    Curr Vasc Pharmacol; 2006 Apr; 4(2):89-93. PubMed ID: 16611151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phosphodiesterase inhibitors.
    Boswell-Smith V; Spina D; Page CP
    Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S252-7. PubMed ID: 16402111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms.
    McKeage K
    Clin Drug Investig; 2013 Jan; 33(1):71-91. PubMed ID: 23288694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.